Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14854802 | 1.00 | EGFR (0.72) | EGFRERBB2 | |
| SCHEMBL14854799 | 1.00 | EGFR (0.72) | EGFRERBB2 | |
| SCHEMBL14854806 | 1.00 | EGFR (0.72) | EGFRERBB2 | |
| SCHEMBL14854777 | 0.96 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL14854778 | 0.96 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL14854780 | 0.96 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL14854781 | 0.96 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL21569040 | 0.91 | EGFR (0.59) | EGFRERBB2 | |
| SCHEMBL27893943 | 0.91 | EGFR (0.66) | EGFRERBB2 | |
| SCHEMBL27893989 | 0.91 | EGFR (0.66) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | claimed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | claimed |
| EP-3222620-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-09-27 | — | — | EP | claimed |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | US | claimed |
| US-9676724-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | claimed |
| EP-2581372-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-06-07 | — | — | EP | claimed |
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2016-06-30 | — | — | US | claimed |
| US-9187458-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-11-17 | — | — | US | claimed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | claimed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | claimed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| EP-3222620-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-09-27 | — | — | EP | disclosed |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-9676724-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| EP-2581372-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-06-07 | — | — | EP | disclosed |
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
| US-9187458-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246443-B2 | Cyanoquinoline derivatives | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885 |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885 |
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885 |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.